Our data indicate that disruption of Atm/Atmin function not only inhibits GBM initiation in Trp53-deficient animals, but also reduces the tumorigenic potential of established human glioma cells, suggesting that ATM inhibitors might be valuable tools in GBM therapy. The gene discussed is ATM; the disease is glioblastoma.